Charles River, Gazi University Partner to Develop Advanced Therapies

Charles River Laboratories International Inc. and Gazi University Faculty of Medicine have entered a gene therapy contract development and manufacturing organization (CDMO) collaboration.

Charles River will supply Gazi University with off-the-shelf research-grade AAV plasmids, offering a pre-manufactured and ready-to-use option for early-stage gene therapy programs. These plasmids are produced with animal component-free methods and are royalty-free, designed to accelerate projects and reduce costs.

“We are excited to build a strong collaboration with Gazi University,” said Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River. “Leveraging cell and gene therapy CDMO expertise will enable the Faculty of Medicine to test and ultimately transform ground-breaking concepts into real-world therapies.”

“We are very happy to enter this strategic collaboration, bringing together academic innovation and CDMO expertise to accelerate the development of advanced therapies,” commented Prof. Fatih Ezgü, MD, Professor of Pediatrics and Head of the Department of Pediatric Genetics at Gazi University Faculty of Medicine. “This partnership marks a significant milestone in our mission to pioneer transformative therapies for rare diseases, and we look forward to the progress we can achieve together.”

More Charles River News

In December, Charles River announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP).